Beyond Air Inc (XAIR)

$3.24 +0.08 (2.53%)
Market Cap 13.65M
Revenue (ttm) 3.71M
Net Income (ttm) -46.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,256.87%
Debt to Equity Ratio 0.68
Volume 137,600
Avg Vol 161,898
Day's Range N/A - N/A
Shares Out 4.32M
Stochastic %K 24%
Beta 0.22
Analysts Strong Sell
Price Target $26.67

Company Profile

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiol...

Industry: Medical Devices
Sector: Healthcare
Phone: 516 665 8200
Address:
900 Stewart Avenue, Suite 301, Garden City, United States
VernCapital
VernCapital Jul. 15 at 7:52 PM
$XAIR current price is 0.1550
1 · Reply
wjbdh
wjbdh Jul. 15 at 4:40 PM
$XAIR if the shorts couldnt kill it before RS, they are no more likely to kill it now. we just have to wait it out.
1 · Reply
TheChetSteadman
TheChetSteadman Jul. 15 at 4:10 PM
$XAIR just run, you POS. Everybody wants to make money
0 · Reply
Fufat
Fufat Jul. 15 at 2:23 PM
$XAIR Seems to be a lot of shorts here wanting to keep it his down. The current price action confirms it. With a really low float that could change real fast if all of a sudden there was a huge influx of buying. IMO. Good Luck To All!
1 · Reply
MRCPLS
MRCPLS Jul. 15 at 1:23 PM
$XAIR I think beyond air is crushing inomax and catching up quickly.
1 · Reply
MRCPLS
MRCPLS Jul. 15 at 12:38 PM
$XAIR apparently in June presentation already had 65 hospitals and counting... Wasn't it 45 at last earnings?
1 · Reply
TheChetSteadman
TheChetSteadman Jul. 15 at 12:12 PM
$XAIR reverse split, stock immediately falls 15% and nothing from the company. I'm convinced they've thrown in the towel. They surely don't care about investors anymore.
1 · Reply
stocktwitsoptions
stocktwitsoptions Jul. 15 at 11:39 AM
$NXTC $PASG $XAIR post reverse split low float
0 · Reply
McLovin55
McLovin55 Jul. 14 at 8:49 PM
$XAIR Shorts are going to take this turd back down to 20 cents.
1 · Reply
AirjudUnbanned
AirjudUnbanned Jul. 14 at 8:46 PM
$XAIR
0 · Reply
Latest News on XAIR
Beyond Air, Inc. (XAIR) Q4 2025 Earnings Call Transcript

Jun 17, 2025, 9:53 PM EDT - 4 weeks ago

Beyond Air, Inc. (XAIR) Q4 2025 Earnings Call Transcript

Beyond Air Stock Dips After Mixed Q4 Results: Here's What To Know

Jun 17, 2025, 4:32 PM EDT - 4 weeks ago

Beyond Air Stock Dips After Mixed Q4 Results: Here's What To Know

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jun 17, 2025, 4:01 PM EDT - 4 weeks ago

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

Jun 16, 2025, 8:00 AM EDT - 4 weeks ago

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

Top Wall Street Forecasters Revamp Beyond Air Expectations Ahead Of Q4 Earnings

Jun 16, 2025, 7:20 AM EDT - 4 weeks ago

Top Wall Street Forecasters Revamp Beyond Air Expectations Ahead Of Q4 Earnings

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

May 20, 2025, 8:00 AM EDT - 2 months ago

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

Apr 21, 2025, 4:05 PM EDT - 3 months ago

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

Apr 15, 2025, 4:05 PM EDT - 3 months ago

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Apr 9, 2025, 4:05 PM EDT - 3 months ago

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

Mar 31, 2025, 8:00 AM EDT - 3 months ago

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Mar 24, 2025, 4:05 PM EDT - 4 months ago

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

Mar 11, 2025, 7:30 AM EDT - 4 months ago

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

Mar 6, 2025, 4:05 PM EST - 4 months ago

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

Beyond Air, Inc. (XAIR) Q3 2025 Earnings Call Transcript

Feb 10, 2025, 7:25 PM EST - 5 months ago

Beyond Air, Inc. (XAIR) Q3 2025 Earnings Call Transcript

Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Feb 10, 2025, 4:05 PM EST - 5 months ago

Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Feb 5, 2025, 9:29 AM EST - 5 months ago

Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Jan 27, 2025, 4:05 PM EST - 6 months ago

Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia

Jan 24, 2025, 9:15 AM EST - 6 months ago

Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia

National Advertising Division Recommends Beyond Air Discontinue or Modify Comparative Safety Claims for its iNO Products

Dec 9, 2024, 11:00 AM EST - 7 months ago

National Advertising Division Recommends Beyond Air Discontinue or Modify Comparative Safety Claims for its iNO Products

Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

Dec 3, 2024, 4:05 PM EST - 8 months ago

Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

Beyond Air Receives CE Mark in Europe for the LungFit® PH System

Dec 2, 2024, 7:30 AM EST - 8 months ago

Beyond Air Receives CE Mark in Europe for the LungFit® PH System

NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board

Nov 26, 2024, 7:30 AM EST - 8 months ago

NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board

Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:05 PM EST - 8 months ago

Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference

Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript

Nov 11, 2024, 7:56 PM EST - 8 months ago

Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Nov 11, 2024, 4:05 PM EST - 8 months ago

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Oct 29, 2024, 4:22 PM EDT - 9 months ago

Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 7, 2024, 7:00 AM EDT - 10 months ago

Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks

Oct 2, 2024, 7:30 AM EDT - 10 months ago

Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks

Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed

Sep 27, 2024, 7:34 AM EDT - 10 months ago

Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed

Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital

Sep 27, 2024, 7:32 AM EDT - 10 months ago

Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital

Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Sep 27, 2024, 7:30 AM EDT - 10 months ago

Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 23, 2024, 8:00 AM EDT - 10 months ago

Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia

Jul 31, 2024, 4:15 PM EDT - 1 year ago

Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia

Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

Jul 23, 2024, 4:05 PM EDT - 1 year ago

Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024

Jul 16, 2024, 4:05 PM EDT - 1 year ago

Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024

Beyond Air, Inc. (XAIR) Q4 2024 Earnings Call Transcript

Jun 24, 2024, 5:48 PM EDT - 1 year ago

Beyond Air, Inc. (XAIR) Q4 2024 Earnings Call Transcript

Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Jun 24, 2024, 4:15 PM EDT - 1 year ago

Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday

Jun 24, 2024, 3:32 AM EDT - 1 year ago

Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday

EPAC OMIC ITI STOK

Beyond Air® Appoints David Webster as Chief Commercial Officer

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Beyond Air® Appoints David Webster as Chief Commercial Officer

Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)

Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast

May 23, 2024, 4:09 PM EDT - 1 year ago

Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast

Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants

Mar 20, 2024, 9:00 AM EDT - 1 year ago

Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants

Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript

Feb 13, 2024, 2:37 AM EST - 1 year ago

Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024

Feb 12, 2024, 4:05 PM EST - 1 year ago

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024

Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast

Jan 18, 2024, 8:00 AM EST - 1 year ago

Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast

Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors

Dec 27, 2023, 7:30 AM EST - 1 year ago

Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

Nov 15, 2023, 4:05 PM EST - 1 year ago

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

Beyond Air, Inc. (XAIR) Q2 2024 Earnings Call Transcript

Nov 13, 2023, 7:07 PM EST - 1 year ago

Beyond Air, Inc. (XAIR) Q2 2024 Earnings Call Transcript

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024

Nov 13, 2023, 4:05 PM EST - 1 year ago

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024

Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

VernCapital
VernCapital Jul. 15 at 7:52 PM
$XAIR current price is 0.1550
1 · Reply
wjbdh
wjbdh Jul. 15 at 4:40 PM
$XAIR if the shorts couldnt kill it before RS, they are no more likely to kill it now. we just have to wait it out.
1 · Reply
TheChetSteadman
TheChetSteadman Jul. 15 at 4:10 PM
$XAIR just run, you POS. Everybody wants to make money
0 · Reply
Fufat
Fufat Jul. 15 at 2:23 PM
$XAIR Seems to be a lot of shorts here wanting to keep it his down. The current price action confirms it. With a really low float that could change real fast if all of a sudden there was a huge influx of buying. IMO. Good Luck To All!
1 · Reply
MRCPLS
MRCPLS Jul. 15 at 1:23 PM
$XAIR I think beyond air is crushing inomax and catching up quickly.
1 · Reply
MRCPLS
MRCPLS Jul. 15 at 12:38 PM
$XAIR apparently in June presentation already had 65 hospitals and counting... Wasn't it 45 at last earnings?
1 · Reply
TheChetSteadman
TheChetSteadman Jul. 15 at 12:12 PM
$XAIR reverse split, stock immediately falls 15% and nothing from the company. I'm convinced they've thrown in the towel. They surely don't care about investors anymore.
1 · Reply
stocktwitsoptions
stocktwitsoptions Jul. 15 at 11:39 AM
$NXTC $PASG $XAIR post reverse split low float
0 · Reply
McLovin55
McLovin55 Jul. 14 at 8:49 PM
$XAIR Shorts are going to take this turd back down to 20 cents.
1 · Reply
AirjudUnbanned
AirjudUnbanned Jul. 14 at 8:46 PM
$XAIR
0 · Reply
Xairian
Xairian Jul. 14 at 8:29 PM
$XAIR Bouncing up(+8%) after hours. This will be volatile for a while.
1 · Reply
TwongStocks
TwongStocks Jul. 14 at 8:26 PM
Today's reverse split results. $GORV 1 for 30. Previous close $0.2394, $7.182 split-adjusted Today's close $7.66 🟢Up 6.66% $HTOO 1 for 35. Previous close $0.1624, $5.684 split-adjusted Today's close $3.96 🔴Down 30.33% $NXTC 1 for 12. Previous close $0.395, $4.74 split-adjusted Today's close $4.90 🟢Up 3.38% $XAIR 1 for 20. Previous close $0.1726, $3.452 split-adjusted Today's close $3.05 🔴Down 11.65% $PASG 1 for 20. Previous close $0.4009, $8.018 split-adjusted Today's close $6.79 🔴Down 15.32% Not tracking any reverse splits for Tuesday.
2 · Reply
deerix
deerix Jul. 14 at 7:50 PM
$XAIR Added a bit here, that's it for now
0 · Reply
Prof_Gulliver
Prof_Gulliver Jul. 14 at 7:41 PM
$XAIR Another all time low, and 4 more days like today and it will be back under $1 and they will never regain compliance. I said the 1:20 might not give them enough cushion, and it was just another catastrophic decision by Lisi. Beyond Air? It’s Beyond Comprehension how this destructive and incompetent CEO still has a job let alone allowed to make any decisions.
1 · Reply
Fufat
Fufat Jul. 14 at 7:30 PM
$XAIR According to OTC Market Group, currently there are only 4,639,739 outstanding shares. That is INSANE!
1 · Reply
TheChetSteadman
TheChetSteadman Jul. 14 at 7:22 PM
$XAIR if Lisi had any sense, they'd release some kind of PR, anything, to give this a boost
1 · Reply
Togdjclecj
Togdjclecj Jul. 14 at 7:22 PM
$XAIR If anyone did not expect this, it's time to quit trading.
0 · Reply
VernCapital
VernCapital Jul. 14 at 7:14 PM
$XAIR and here in is the problem with R/s getting bled to death
1 · Reply
bluehens422
bluehens422 Jul. 14 at 6:59 PM
$XAIR Buy it < $3 while you still can. 1st PR and this will rocket.
1 · Reply
MRCPLS
MRCPLS Jul. 14 at 6:46 PM
$XAIR already at 2.96.... holy crap
2 · Reply
TheChetSteadman
TheChetSteadman Jul. 14 at 6:42 PM
$XAIR yep, i knew it1
0 · Reply
TheChetSteadman
TheChetSteadman Jul. 14 at 6:24 PM
$XAIR I bought 2000 shares at 3.16. I'm 100% certain I'll regret it but thats ok because I'm an idiot. Very small float now so a squeeze is much more likely.
1 · Reply